Cargando…

Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence

Beta-thalassemia represents a heterogeneous group of haemoglobin inherited disorders, among the most common genetic diseases in the world, frequent in the Mediterranean basin. As beta-thalassemia patients’ survival has increased over time, previously unknown complications are observed with increasin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangia, Alessandra, Bellini, Davide, Cillo, Umberto, Laghi, Andrea, Pelle, Giuseppe, Valori, Vanna Maria, Caturelli, Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398335/
https://www.ncbi.nlm.nih.gov/pubmed/32746786
http://dx.doi.org/10.1186/s12876-020-01391-z
_version_ 1783565945076187136
author Mangia, Alessandra
Bellini, Davide
Cillo, Umberto
Laghi, Andrea
Pelle, Giuseppe
Valori, Vanna Maria
Caturelli, Eugenio
author_facet Mangia, Alessandra
Bellini, Davide
Cillo, Umberto
Laghi, Andrea
Pelle, Giuseppe
Valori, Vanna Maria
Caturelli, Eugenio
author_sort Mangia, Alessandra
collection PubMed
description Beta-thalassemia represents a heterogeneous group of haemoglobin inherited disorders, among the most common genetic diseases in the world, frequent in the Mediterranean basin. As beta-thalassemia patients’ survival has increased over time, previously unknown complications are observed with increasing frequency. Among them, an increased risk of hepatocellular carcinoma (HCC) has been registered. Our aim is to reduce inequalities in diagnosis and treatment and to offer patients univocal recommendations in any institution. The members of the panel - gastroenterologists, radiologists, surgeons and oncologists -were selected on the basis of their publication records and expertise. Thirteen clinical questions, derived from clinical needs, and an integration of all the committee members’ suggestions, were formulated. Modified Delphi approach involving a detailed literature review and the collective judgement of experts, was applied to this work. Thirteen statements were derived from expert opinions’ based on the current literature, on recently developed reviews and on technological advancements. Each statement is discussed in a short paragraph reporting the current key evidence. As this is an emerging issue, the number of papers on HCC in beta-thalassemia patients is limited and based on anecdotal cases rather than on randomized controlled studies. Therefore, the panel has discussed, step by step, the possible differences between beta-thalassemia and non beta-thalassemia patients. Despite the paucity of the literature, practical and concise statements were generated. This paper offers a practical guide organized by statements describing how to manage HCC in patients with beta-thalassemia.
format Online
Article
Text
id pubmed-7398335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73983352020-08-06 Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence Mangia, Alessandra Bellini, Davide Cillo, Umberto Laghi, Andrea Pelle, Giuseppe Valori, Vanna Maria Caturelli, Eugenio BMC Gastroenterol Review Beta-thalassemia represents a heterogeneous group of haemoglobin inherited disorders, among the most common genetic diseases in the world, frequent in the Mediterranean basin. As beta-thalassemia patients’ survival has increased over time, previously unknown complications are observed with increasing frequency. Among them, an increased risk of hepatocellular carcinoma (HCC) has been registered. Our aim is to reduce inequalities in diagnosis and treatment and to offer patients univocal recommendations in any institution. The members of the panel - gastroenterologists, radiologists, surgeons and oncologists -were selected on the basis of their publication records and expertise. Thirteen clinical questions, derived from clinical needs, and an integration of all the committee members’ suggestions, were formulated. Modified Delphi approach involving a detailed literature review and the collective judgement of experts, was applied to this work. Thirteen statements were derived from expert opinions’ based on the current literature, on recently developed reviews and on technological advancements. Each statement is discussed in a short paragraph reporting the current key evidence. As this is an emerging issue, the number of papers on HCC in beta-thalassemia patients is limited and based on anecdotal cases rather than on randomized controlled studies. Therefore, the panel has discussed, step by step, the possible differences between beta-thalassemia and non beta-thalassemia patients. Despite the paucity of the literature, practical and concise statements were generated. This paper offers a practical guide organized by statements describing how to manage HCC in patients with beta-thalassemia. BioMed Central 2020-08-03 /pmc/articles/PMC7398335/ /pubmed/32746786 http://dx.doi.org/10.1186/s12876-020-01391-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Mangia, Alessandra
Bellini, Davide
Cillo, Umberto
Laghi, Andrea
Pelle, Giuseppe
Valori, Vanna Maria
Caturelli, Eugenio
Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
title Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
title_full Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
title_fullStr Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
title_full_unstemmed Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
title_short Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
title_sort hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398335/
https://www.ncbi.nlm.nih.gov/pubmed/32746786
http://dx.doi.org/10.1186/s12876-020-01391-z
work_keys_str_mv AT mangiaalessandra hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence
AT bellinidavide hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence
AT cilloumberto hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence
AT laghiandrea hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence
AT pellegiuseppe hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence
AT valorivannamaria hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence
AT caturellieugenio hepatocellularcarcinomainadultthalassemiapatientsanexpertopinionbasedoncurrentevidence